Kolkata: Goldline Pharmaceutical IPO is a book build issue designed to mobilise Rs 11.61 crores. One of the positives of the issue is that only fresh shares will be issued to raise this amount and, therefore, the entire proceeds will go to the company. The issue will consist of 0.27 crore shares. The primary issue market is dull so far this year with only 20 mainboard listings. In this tepid market, Goldline Pharmaceutical IPO stands out for triggering interest among potential investors, which has elevated its GMP.

Nagpur-based Goldline Pharmaceuticals is active in the business of marketing pharmaceutical products. It does so under the brand “Goldline.” It has a wide product range which are sold across a large region across Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan and Bihar. Its products are divided into the following segments — Goldline Pharma (with 42 products for orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology and urology); Goldline Cardinal (54 products tailored for diabetologists, endocrinologists, cardiologists and general physicians); Goldline Aayushman (18 items for pediatricians, neonatologists and general practitioners); Goldline InLife (22 products for intensivists, critical care consultants, super specialty surgeons and physicians) and Goldline Wellness (10 products tailored for supportive care in cancer therapy). The company markets products made by third-party manufacturers. The company has 15 manufacturers and seven distributors.

Goldline Pharmaceutical IPO GMP

According to investorgain, Goldline Pharmaceutical SME IPO GMP stood at Rs 16 in early morning of Monday, May 11. It is holding steady at this level for the past two days. Considering an issue price of Rs 43.00, the estimated listing price of Goldline Pharmaceutical shares will be Rs 58 and the listing will be 37.21%. However, it must be kept in mind that GMP is an unofficial indicator, can be very volatile and does not guarantee any listing gain.

Goldline Pharmaceutical IPO price band

Goldline Pharmaceutical IPO opens for subscription on May 12, 2026 and closes on May 14, 2026. The allotment for the Goldline Pharmaceutical IPO is expected to be finalized on May 15, 2026. Goldline Pharmaceutical IPO will list on the BSE SME with a tentative listing date fixed as May 19, 2026.

The Goldline Pharmaceutical IPO price band has been set at Rs 41-43. The minimum investable lot is 3,000 shares btu the minimum application has to be made for 600 shares, or two lots, for which one has to commit Rs 2.58 lakh based on the upper price. HNIs have to bid for three lots or 9,000 shares for which he/she has to pahy Rs 3.87 lakh. Cumulative Capital is the book running lead manager and Bigshare Services is the registrar of the issue. The Market Maker of the company is Nirman Share Brokers.

Goldline Pharmaceutical IPO key dates

Bid opens: tomorrow, May 12, 2026
Bid closes: May 14
Allotment: May 15
Refund: May 18
Credit of shares: May 18
Listing: May 19

(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds, precious metals, commodity, REITs, InvITs and any form of alternative investment instruments and crypto assets.)